Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer.

The policy cites sufficient evidence in guidelines and peer-reviewed literature to demonstrate improved health outcomes and deems Lucid’s EsoGuard Esophageal DNA Test medically necessary for patients who meet American College of Gastroenterology (ACG) screening criteria. According to Lucid, multiple Concert client health plans have already adopted this policy, supporting broader commercial access to EsoGuard and reinforcing the company’s clinical evidence base.

Positive

• Concert coverage policy effective July 2026 for EsoGuard screening of esophageal precancer and cancer
• EsoGuard deemed medically necessary for patients meeting ACG screening criteria under Concert’s policy
• Multiple Concert client health plans have already adopted the EsoGuard coverage policy
• Policy cites sufficient evidence from guidelines and peer-reviewed literature showing improved health outcomes

Negative

• None.

Market Context

PAVM's active S-3 is a resale registration for selling-stockholder shares, with proceeds to the comp...

Analysis

PAVM's active S-3 is a resale registration for selling-stockholder shares, with proceeds to the company only if warrants are exercised. The coverage policy adds access evidence; payer adoption remains the key monitoring point.

Key Figures

Coverage policy effective date: July 2026

1 metrics

Coverage policy effective date July 2026 Concert policy for non-invasive esophageal precancer and cancer screening

Historical Context

5 past events · Latest: May 15 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 15	Q1 earnings report	Negative	+1.2%	Low revenue and net loss accompanied financing and extended cash runway
May 14	Q1 earnings report	Positive	+2.2%	EsoGuard test volume, revenue, financing, and cash runway were reported
May 01	Conference call notice	Neutral	+2.8%	Management scheduled a first-quarter business update and financial-results webcast
Apr 30	Conference call notice	Neutral	-7.0%	Lucid scheduled its first-quarter business update and financial-results webcast
Apr 24	Common stock offering	Negative	-1.9%	Underwritten offering closed with eighteen million dollars in gross proceeds

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions were mixed, with positive and negative developments not consistently matched by same-direction price reactions.

Key Terms

coverage policy, esophageal precancer, medically necessary

3 terms

coverage policy regulatory

"Concert issued a positive coverage policy effective July 2026"

A coverage policy is a set of rules a news outlet or analyst service uses to decide which companies, topics, or securities it will report on and how it will handle conflicts, corrections, and updates. It matters to investors because it explains what information to expect, how comprehensive and impartial that information aims to be, and how the publisher treats errors or relationships that could affect reporting—like a playbook that guides consistent, transparent coverage.

esophageal precancer medical

"for non-invasive screening of esophageal precancer and cancer"

Esophageal precancer describes abnormal cell changes in the lining of the esophagus that are not yet invasive cancer but have a higher risk of becoming malignant over time, like early cracks in paint that can lead to rot if left unchecked. It matters to investors because the need for earlier detection, monitoring and preventive treatments creates market opportunities for diagnostics, drugs and medical devices, and influences regulatory approvals, reimbursement and future revenue potential.

medically necessary medical

"considers Lucid's EsoGuard Esophageal DNA Test medically necessary"

A clinical and insurance standard that says a test, treatment, or supply is appropriate, effective, and needed to diagnose or treat a medical condition. Think of it as a gatekeeper rule: doctors and payers evaluate whether an intervention is medically justified for a specific patient and situation. It matters to investors because this designation often determines whether procedures and products are reimbursed, how quickly they are adopted, and therefore how revenues and costs will play out.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Concert's policy recognizes EsoGuard ^® as the only esophageal precancer test meeting its coverage criteria

NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt.

The policy cites sufficient evidence in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes, and considers Lucid's EsoGuard^® Esophageal DNA Test medically necessary in patients who meet American College of Gastroenterology (ACG) screening criteria.

"Securing this coverage policy is a another significant step toward broad commercial coverage of EsoGuard, as Concert's policies drive adoption by the health plans it serves," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We are encouraged that multiple Concert client health plans have already adopted this coverage policy, further validating the strength of our clinical evidence base. We remain deeply engaged with all of our commercial insurers and their benefit managers across the country as we seek to expand access to EsoGuard precancer testing."

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-secures-commercial-coverage-policy-spanning-multiple-health-plans-for-its-esoguard-esophageal-dna-test-302843758.html

SOURCE Lucid Diagnostics

FAQ

What commercial coverage did Lucid Diagnostics (NASDAQ: LUCD) secure for the EsoGuard test in August 2026?

Lucid Diagnostics secured a positive coverage policy from Concert for EsoGuard in August 2026. According to Lucid Diagnostics, the policy covers non-invasive screening for esophageal precancer and cancer and can be adopted by Concert’s client health plans to expand patient access.

When does Concert’s coverage policy for Lucid Diagnostics’ EsoGuard test become effective?

Concert’s coverage policy for the EsoGuard Esophageal DNA Test is effective starting July 2026. According to Lucid Diagnostics, this policy supports non-invasive screening for esophageal precancer and cancer in eligible patients and can be implemented by Concert’s client health plans.

Why is EsoGuard considered medically necessary under Concert’s policy for LUCD?

EsoGuard is considered medically necessary under Concert’s policy for patients who meet ACG screening criteria. According to Lucid Diagnostics, Concert cited sufficient evidence from published guidelines and peer-reviewed literature showing that EsoGuard-based screening can definitively improve health outcomes in these high-risk individuals.

How many health plans have adopted Concert’s EsoGuard coverage policy for Lucid Diagnostics?

Lucid Diagnostics reports that multiple Concert client health plans have already adopted the EsoGuard coverage policy. According to Lucid Diagnostics, these early adopters support broader commercial coverage and validate the company’s clinical evidence base for non-invasive esophageal precancer and cancer screening.

What role does the American College of Gastroenterology (ACG) play in EsoGuard coverage for LUCD?

The ACG provides screening criteria that determine which patients qualify for medically necessary EsoGuard testing. According to Lucid Diagnostics, Concert’s policy restricts coverage to patients who meet American College of Gastroenterology esophageal screening criteria, aligning reimbursement with established clinical practice guidelines.

How is Lyric connected to the new EsoGuard coverage policy impacting Lucid Diagnostics stock (LUCD)?

Lyric is connected through its acquisition of Concert, the company issuing the coverage policy. According to Lucid Diagnostics, Concert, now owned by Lyric, establishes coverage policies that its client health plans can adopt, including the new EsoGuard policy effective July 2026.